EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure

Paul W Wales iD, Susan Hill, Ian Robinson, Bram P Raphael, Cheney Matthews, Valeria Cohran, Beth Carter, Robert Venick, Samuel Kocoshis

Journal of Pediatric Gastroenterology and Nutrition · 2024-08 · 79 (2) · 290-300

DOI: 10.1002/jpn3.12276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 14.06.2024. Verfasst von Paul W Wales und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Peptides, Short Bowel Syndrome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Patients with short bowel syndrome‐associated intestinal failure (SBS‐IF) require long‐term parenteral nutrition and/or intravenous fluids (PN/IV) to maintain fluid or nutritional balance. We report the long‐term safety, efficacy, and predictors of response in pediatric patients with SBS‐IF receiving teduglutide over 96 weeks.

Methods

This was a pooled, post hoc analysis of two open‐label, long‐term extension (LTE) studies (NCT02949362 and NCT02954458) in children with SBS‐IF. Endpoints included treatment‐emergent adverse events (TEAEs) and clinical response (≥20% reduction in PN/IV volume from baseline). A multivariable linear regression identified predictors of teduglutide response; the dependent variable was mean change in PN/IV volume at each visit over 96 weeks.

Results

Overall, 85 patients were analyzed; 78 patients received teduglutide in the parent and/or LTE studies (any teduglutide [TED] group), while seven patients did not receive teduglutide in either the parent or LTE studies. Most TEAEs were moderate or severe in intensity in both groups. By week 96, 82.1% of patients from the any TED group achieved a clinical response, with a mean fluid decrease of 30.1 mL/kg/day and an energy decrease of 21.6 kcal/kg/day. Colon‐in‐continuity, non‐White race, older age at baseline, longer duration of teduglutide exposure, and increasing length of remaining small intestine were significantly associated with a reduction in mean PN/IV volume requirements.

Conclusions

In pediatric patients with SBS‐IF, teduglutide treatment resulted in long‐term reductions in PN/IV requirements. The degree of PN/IV volume reduction depended on the duration of teduglutide exposure, underlying bowel anatomy, and demographics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsPeptidesShort Bowel SyndromeAdolescentChildChild, PreschoolFemaleHumansInfantMaleIntestinal FailureParenteral NutritionTreatment Outcome

Stichwörter der Autor:innen

GattexRevestiveglucagon‐like peptide‐2parenteral nutritionpediatrics

Substanzen

Gastrointestinal AgentsPeptidesteduglutide

Autor:innen und Institutionen

  • Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Takeda Pharmaceuticals, Inc., Lexington, Massachusetts, USA.
  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, UCLA Mattel Children's Hospital, Los Angeles, California, USA.

ORCID-Profile: Paul W Wales

Förderung

  • Takeda Pharmaceuticals U.S.A., Inc.

Zitieren

APA

Wales, P. W., Hill, S., Robinson, I., Raphael, B. P., Matthews, C., Cohran, V., Carter, B., Venick, R., & Kocoshis, S. (2024). Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure. Journal of Pediatric Gastroenterology and Nutrition, 79(2), 290-300. https://doi.org/10.1002/jpn3.12276

Vancouver

Wales PW, Hill S, Robinson I, Raphael BP, Matthews C, Cohran V, et al. Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure. Journal of Pediatric Gastroenterology and Nutrition. 2024;79(2):290-300. doi:10.1002/jpn3.12276

BibTeX
@article{Wales2024,
  author = {Wales, Paul W and Hill, Susan and Robinson, Ian and Raphael, Bram P and Matthews, Cheney and Cohran, Valeria and Carter, Beth and Venick, Robert and Kocoshis, Samuel},
  title = {Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  volume = {79},
  number = {2},
  pages = {290--300},
  doi = {10.1002/jpn3.12276}
}
Kostenlos starten →